Yi Mei (怡玫)怡玫
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
批准文号:NMPA approval number: 国药准字H20030624
生产企业Manufacturer
- 福安药业集团湖北人民制药有限公司Chinese legal name: 福安药业集团湖北人民制药有限公司
主要成分Active Ingredients
- 烟酸占替诺Yansuan Zhanti Nuo
药物知识说明
国药准字H20030624是一种在国家药监局注册认定的药品。该药品含有相关活性成分。
该药品关联的活性成分包括：烟酸占替诺Yansuan Zhanti Nuo。这些成分信息来自国家药监局数据库。
您可以探索含有相同成分的其他药品：烟酸占替诺-ad61e157成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 怡玫) is a medicine registered with the national drug regulatory authority. It contains active ingredient(s) as recorded.
Active ingredients associated with this product: 烟酸占替诺Yansuan Zhanti Nuo.
Explore other medicines containing the same ingredient: 烟酸占替诺 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 怡玫Recorded Chinese name: 怡玫
- 剂型Dosage form: 注射剂Injection
- 规格Specification: 0.3g0.3 g
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 福安药业集团湖北人民制药有限公司Chinese legal name: 福安药业集团湖北人民制药有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20030624
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20030624
Manufacturer
Chinese legal name: 福安药业集团湖北人民制药有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Protect from light and keep tightly closed.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20030624
生产企业
福安药业集团湖北人民制药有限公司(国产)
适应症
本品用于缺血性脑血管病和外周血管循环障碍。
用法用量
起始剂量0.3g/天，逐渐增加至0.6～0.9g/天，加入5%葡萄糖注射液中静脉滴注。
不良反应
用药初期部分病人可有面颊潮红、口干、胸闷、皮疹、四肢红斑及风团，极个别患者出现脑出血及脑疝。
禁忌
1.急性心肌梗塞、出血性脑血管病、各种急性出血者、脱水、二尖瓣狭窄及明显心功能不全者禁用。|2.对本品过敏者禁用。
注意事项
1.静滴时应控制滴速，以30～40滴/分为宜，不得过50滴/分，同时观察患者的自觉症状及患者血压、心率、脉率的变化。|2.消化性溃疡及血压不稳患者慎用。?|3.临床应用时，应密切注意患者颅压变化情况。|4.若发生过敏，应立即停药，并根据临床具体情况而采取以下药物或方法治疗，肾上腺素及其它抢救措施，包括吸氧、静脉输液、抗组织胺药、皮质类固醇药等。|5.本品主要经肝脏代谢，肝功能不全患者慎用。
贮藏
遮光，密闭保存。
规格
0.3g
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.